Therapies developed on a foundation of experience
We have a deep understanding of - and experience in - nervous system research, product development and commercialization. This expertise enables us to focus on therapies that have a potential to improve the lives of people with neurological disorders. In this section you can learn more about our pipeline programs as well as our approved products.
INBRIJA® (levodopa inhalation powder)
Read More
Product Pipeline
GGF2 (Cimaglermin alfa) – GGF2 is a member of the neuregulin growth factor family, and has been shown to promote recovery after neurological injury, as well as to enhance heart function in animal models of heart failure. GGF2 showed positive effects on cardiac function in the two Phase 1 clinical studies conducted to date. The Phase 1b trial assessed three doses of cimaglermin alfa in people with heart failure, but discontinued enrollment and then received an FDA clinical hold based on the occurrence of a case of markedly elevated bilirubin and liver enzymes. The FDA clinical hold was lifted in April 2017 after Acorda presented additional data on this effect, but the Company has not restarted any clinical studies. Acorda is currently deferring further investment in this program, and is considering next steps, which could include potential partnering or out-licensing.
